# OnCo record mychoice-cdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mychoice-cdx/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mychoice-cdx" ;
  schema:name "myChoice CDx"@en ;
  schema:description "A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors."@en ;
  schema:url <https://onco.cc/drugs/mychoice-cdx/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190014> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Tumour HRD genomic instability companion diagnostic test" ;
  schema:alternateName "myChoice CDx" ;
  onco:approval "US 2019: Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer", "US 2020: Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/myriad-genetics/> ;
  onco:terms <https://onco.cc/terms/hrd/> ;
  onco:trials <https://onco.cc/trials/paola-1/>, <https://onco.cc/trials/prima/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/>, <https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-tutt-nat-med/> .